Literature DB >> 15581411

Cannabinoid/opioid crosstalk in the central nervous system.

Javier Corchero1, Jorge Manzanares, José A Fuentes.   

Abstract

Promising therapeutic uses and a great variety of pharmacological effects are the leading forces that focus actual cannabinoid research. Cannabinoid and opioid systems share neuroanatomical, neurochemical, and paharmacological features. This fact supports the notion that actions induced by each one of these types of drugs involved an interaction between the endogenous opioid and endocannabinoid neuronal systems. Over the last decade our group and others have investigated cannabinoid/opioid crosstalk in the central nervous system by studying the mechanisms underlying pharmacological and biochemical interactions between the two systems in experimental paradigms of antinociception, drug reinforcement, and anxiety. The goal of this review is to revise the latest work done on this subject, with special emphasis on the research done with genetically modified animals. Whereas clinical progress is going ahead slowly, basic research in this area is progressing rapidly. Clinical applications derived from the cannabinoid/opioid crosstalk and based tightly on medical evidence are yet to come, but it is hoped that knowledge of this central messenger interaction will help to develop new alternatives for the treatment of some pathological states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15581411     DOI: 10.1615/critrevneurobiol.v16.i12.170

Source DB:  PubMed          Journal:  Crit Rev Neurobiol        ISSN: 0892-0915


  16 in total

1.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

2.  Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice.

Authors:  Mauro A M Carai; Giancarlo Colombo; Gian Luigi Gessa; Ratnakumar Yalamanchili; Balapal S Basavarajappa; Balapal S Basavarajppa; Basalingappa L Hungund
Journal:  Br J Pharmacol       Date:  2006-07-17       Impact factor: 8.739

Review 3.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 4.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

5.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 6.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 7.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

Review 8.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.

Authors:  Federico Massa; Martin Storr; Beat Lutz
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

9.  Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.

Authors:  Jillian L Scavone; Ken Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2009-11-18       Impact factor: 3.252

10.  Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.

Authors:  R Capasso; F Borrelli; M G Cascio; G Aviello; K Huben; J K Zjawiony; P Marini; B Romano; V Di Marzo; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-07-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.